An observational cohort study on the nutrition status of patients with advanced gastric cancer who receive combination chemotherapy with ramucirumab and a taxane - Balast study

St.Marianna University School of Medicine0 sites26 target enrollmentSeptember 3, 2019

Conditionsadvanced gastric cancer

Overview

Phase: 未知
Intervention: Not specified
Conditions: advanced gastric cancer
Sponsor: St.Marianna University School of Medicine
Enrollment: 26
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

September 3, 2019

End Date

September 30, 2021

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

St.Marianna University School of Medicine

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•Patients fulfilling any of the following criteria will not be enrolled in any component of the study. Patients who: \- Are unable to receive nutrition orally, \- Have documented and/or symptomatic brain or leptomeningeal metastases, \- Have experienced any episodes of Grade 3\-4 gastrointestinal bleeding within 3 months prior to enrollment, \- Have experienced any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina within 6 months prior to enrollment, \- Have an ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, uncontrolled thrombotic or hemorrhagic disorder, or any other serious uncontrolled medical disorders in the opinion of the investigator, \- Have an ongoing or active psychiatric illness or a social situation that would limit compliance with the study requirements, \- Have uncontrolled or poorly controlled hypertension despite standard medical management, \- Have had a serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to enrollment, \- Have undergone major surgery within 28 days prior to randomization or the placement of a subcutaneous venous access device within 7 days prior to enrollment, \- Are receiving chronic antiplatelet therapy including the use of aspirin, nonsteroidal anti\-inflammatory drugs (NSAIDs, including ibuprofen, naproxen, and others), dipyridamole, clopidogrel, or similar agents with the exception of once\-daily aspirin use (maximum dose, 325 mg/day), and \- Are scheduled to receive elective or planned major surgery during the course of the study.